A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Launched by BRISTOL-MYERS SQUIBB · Feb 2, 2024
Trial Information
Current as of July 05, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called mavacamten to see how well it works for adolescents with a condition known as obstructive hypertrophic cardiomyopathy (HCM). HCM is a heart condition that causes the heart muscle to become thick, making it harder for the heart to pump blood. The trial aims to find out if mavacamten can help relieve symptoms and improve heart function in young patients who are experiencing these issues.
To join the study, participants must be diagnosed with HCM and have symptoms along with a specific type of blockage in the heart's left ventricle. The trial is open to both boys and girls aged 12 to 17. It's important to note that some patients may not be eligible if they have other heart conditions or if they are planning to change their current heart treatment. Those who participate will be monitored closely throughout the study to ensure their safety and to gather information on how well the medication works.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of HCM
- • Presence of LVOT obstruction
- • Presence of symptoms
- Exclusion Criteria:
- • Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
- • Evidence of LVEF \<50% in prior 6 months
- • Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)
- • Other protocol-defined Inclusion/Exclusion criteria apply.
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Cincinnati, Ohio, United States
Houston, Texas, United States
Columbus, Ohio, United States
Sydney, New South Wales, Australia
Boston, Massachusetts, United States
New York, New York, United States
Edmonton, Alberta, Canada
Memphis, Tennessee, United States
Paris, , France
Bronx, New York, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Los Angeles, California, United States
Aurora, Colorado, United States
Toronto, Ontario, Canada
Clayton, Victoria, Australia
Chicago, Illinois, United States
Ann Arbor, Michigan, United States
New Hyde Park, New York, United States
Madrid, , Spain
Houston, Texas, United States
Memphis, Tennessee, United States
Napoli, , Italy
Ann Arbor, Michigan, United States
Salt Lake City, Utah, United States
New York, New York, United States
Palo Alto, California, United States
Parkville, Victoria, Australia
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Oakland, California, United States
San Diego, California, United States
Aurora, Colorado, United States
Saint Petersburg, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Boston, Massachusetts, United States
Saint Louis, Missouri, United States
Morristown, New Jersey, United States
Bronx, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
New York, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Salt Lake City, Utah, United States
Charlottesville, Virginia, United States
Madison, Wisconsin, United States
Sydney, New South Wales, Australia
Clayton, Victoria, Australia
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Paris, , France
Pessac, , France
Berlin, Be, Germany
Munich, By, Germany
Drimnagh, D, Ireland
Firenze, Fi, Italy
Genova, Ge, Italy
Barcelona, B, Spain
Granada, Gr, Spain
Madrid, M, Spain
A Coruna, , Spain
Madrid, , Spain
Belfast, Bfs, United Kingdom
London, , United Kingdom
Indianapolis, Indiana, United States
San Diego, California, United States
Saint Louis, Missouri, United States
Pittsburgh, Pennsylvania, United States
Charlottesville, Virginia, United States
Phoenix, Arizona, United States
Dallas, Texas, United States
Pessac, , France
Atlanta, Georgia, United States
Philadelphia, Pennsylvania, United States
Pessac, , France
Birmingham, Alabama, United States
Morristown, New Jersey, United States
Morristown, New Jersey, United States
Dublin 12, D12 N512, , Ireland
Munich, By, Germany
Atlanta, Georgia, United States
Napoli, , Italy
Los Angeles, California, United States
Palo Alto, California, United States
Austin, Texas, United States
Berlin, Be, Germany
Barcelona, B, Spain
Dublin 12, D12 N512, , Ireland
Saint Petersburg, Florida, United States
Genova, Ge, Italy
Charlotte, North Carolina, United States
Firenze, Fi, Italy
London, , United Kingdom
San Diego, California, United States
Philadelphia, Pennsylvania, United States
Belfast, Bfs, United Kingdom
Birmingham, Alabama, United States
Atlanta, Georgia, United States
Morristown, New Jersey, United States
Memphis, Tennessee, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported